Allogene’s Cema-cel Gains FDA Fast Track and RMAT Designations for LBCL Treatment
Allogene Therapeutics has announced that its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (cema-cel), has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA) for treating adults with large B-cell lymphoma (LBCL).
The designations support accelerated development and regulatory engagement for cema-cel as a potential first-line consolidation therapy.
For patients who complete initial treatment and achieve complete or partial response but remain positive for minimal residual disease (MRD).
Cema-cel is being evaluated in the pivotal ALPHA3 trial, which uses Natera’s CLARITY™ MRD assay to identify LBCL patients at increased risk of relapse after first-line chemoimmunotherapy.
The study compares outcomes between patients receiving a single dose of cema-cel and those under standard observation.
Interim trial data showed that 58.3% of patients treated with cema-cel achieved MRD negativity compared with 16.7% in the observation group.
The therapy also demonstrated a favourable safety profile, with no treatment-related serious adverse events, cytokine release syndrome, neurotoxicity syndrome, graft-versus-host disease or high-grade infections reported.
The FDA designations highlight the potential of cema-cel as an accessible, off-the-shelf CAR T-cell therapy option that could expand treatment availability for LBCL patients and support earlier intervention to reduce relapse risk.
